Grey matter changes in cognitively impaired Parkinson's disease patients

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Rektorova, Irena ^a   Biundo, Roberta ^b   Marecek, Radek ^a   Weis, Luca ^b   Aarsland, Dag ^c,d   Antonini, Angelo ^b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b Center for Parkinson's Disease and Movement Disorder Fondazione Ospedale San Camillo Istituto di Ricovero e Cura a Carattere Scientifico   (Italy)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AMYGDALOID NUCLEUS; ARTICLE; BRAIN SIZE; CEREBELLUM; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; DEPTH PERCEPTION; FEMALE; FRONTAL LOBE; FUSIFORM GYRUS; GRAY MATTER; HIPPOCAMPUS; HUMAN; INFERIOR TEMPORAL GYRUS; MAJOR CLINICAL STUDY; MALE; MESENCEPHALON; MIDDLE TEMPORAL GYRUS; MILD COGNITIVE IMPAIRMENT; MORPHOMETRICS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAHIPPOCAMPAL GYRUS; PARIETAL LOBE; PARKINSON DISEASE; PHONEME; SOURCE BASED MORPHOMETRY; SUPERIOR TEMPORAL GYRUS; TEMPORAL LOBE;

AGED; CEREBELLUM; DEMENTIA; FEMALE; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MESENCEPHALON; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PARIETAL LOBE; PARKINSON DISEASE; TEMPORAL LOBE;

EID: 84908111231     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085595     Document Type: Article

References (56)

1. Svenningsson P, Westman E, Ballard C, Aarsland D (2012) Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol 11:697-707.
2. Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, et al. (2010) Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 75:1062-9.
3. Ibarretxe-Bilbao N, Tolosa E, Junque C, Marti MJ (2009) MRI and cognitive impairment in Parkinson's disease. Mov Disord 24 (Suppl 2):S748-53.
4. Hattori T, Orimo S, Aoki S, Ito K, Abe O, et al. (2012) Cognitive status correlates with white matter alteration in Parkinson's disease. Hum Brain Mapp 33:727-39.
5. Melzer TR, Watts R, MacAskill MR, Pitcher TL, Livingston L, et al. (2012) Grey matter atrophy in cognitively impaired Parkinson's disease. J Neurol Neurosurg Psychiatry 83:188-94.
6. Dalaker TO, Zivadinov R, Larsen JP, Beyer MK, Cox JL, et al. (2010) Gray matter correlations of cognition in incident Parkinson's disease. Mov Disord 25:629-33.
7. Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, et al. (2012) Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 27:349-56.
8. Xu L, Groth KM, Pearlson G, Schretlen DJ, Calhoun VD (2009) Source-based morphometry: the use of independent component analysis to identify gray matter differences with application to schizophrenia. Hum Brain Mapp 30:711-24.
9. Kaspárek T, Marecek R, Schwarz D, Kucerova H, Marecek R, et al. (2010) Source-based morphometry of gray matter volume in men with first-episode schizophrenia. Hum Brain Mapp 31:300-10.
10. Ward CD, Gibb WR. (1990) Research diagnostic criteria for Parkinson's disease. Adv Neurol 53:245-9.
11. Mathuranath PS, Nestor PJ, Berrios GE, Rakowicz W, Hodges JR (2000) A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology 55:1613-20.
12. Hummelova-Fanfrdlova Z, Rektorova I, Sheardova K, Bartos A, Linek V, et al. (2009) Ceska adaptace Addenbrookskeho kognitivnýho testu. Ceskoslovenska psychologie 53:376-388.
13. Reyes MA, Perez-Lloret S, Roldan Gerschcovich E, Martin ME, Leiguarda R, et al. (2009) Addenbrooke's Cognitive Examination validation in Parkinson's disease. Eur J Neurol 16:142-7.
14. Kaszás B, Kovács N, Balás I, Kállai J, Aschermann Z, et al. (2012) Sensitivity and specificity of Addenbrooke's Cognitive Examination, Mattis Dementia Rating Scale, Frontal Assessment Battery and Mini Mental State Examination for diagnosing dementia in Parkinson's disease. Parkinsonism Relat Disord 18:553-6.
15. Rittman T, Ghosh BC, McColgan P, Breen DP, Evans J, et al. (2013) The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. J Neurol Neurosurg Psychiatry 84:544-51.
16. Krajcovicova L, Mikl M, Marecek R, Rektorova I (2012) The default mode network integrity in patients with Parkinson's disease is levodopa equivalent dose-dependent. J Neural Transm 119:443-54.
17. Rektorova I, Krajcovicova L, Marecek R, Mikl M (2012) Default mode network and extrastriate visual resting state network in patients with Parkinson's disease dementia. Neurodegener Dis 10:232-7.
18. McColgan P, Evans JR, Breen DP, Mason SL, Barker RA, et al. (2012) Addenbrooke's Cognitive Examination-Revised for mild cognitive impairment in Parkinson's disease. Mov Disord 27:1173-7.
19. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, et al. (2007) Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 22:1689-707. (Pubitemid 47597592)
20. Li YO, Adali T, Calhoun VD (2007) Estimating the number of independent components for functional magnetic resonance imaging data. Hum Brain Mapp 28:1251-66. (Pubitemid 350077488)
21. Burton EJ, McKeith IG, Burn DJ, Williams ED, O'Brien JT (2004) Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 127:791-800. (Pubitemid 38478524)
22. Nagano-Saito A, Washimi Y, Arahata Y, Kachi T, Lerch JP, et al. (2005) Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 64: 224-9.
23. Summerfield C, Junqué C, Tolosa E, Salgado-Pineda P, Gómez-Ansón B, et al. (2005) Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch Neurol 62:281-5. (Pubitemid 40204750)
24. Tam CW, Burton EJ, McKeith IG, Burn DJ, O'Brien JT (2005) Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies. Neurology 64:861-5. (Pubitemid 40316326)
25. Beyer MK, Janvin CC, Larsen JP, Aarsland D (2007) A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry 78:254-9. (Pubitemid 46579662)
26. Song SK, Lee JE, Park HJ, Sohn YH, Lee JD, et al. (2011) The pattern of cortical atrophy in patients with Parkinson's disease according to cognitive status. Mov Disord 26:289-96.
27. Weintraub D, Doshi J, Koka D, Davatzikos C, Siderowf AD, et al. (2011) Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch Neurol 68:1562-8.
28. Biundo R, Formento-Dojot P, Facchini S, Vallelunga A, Ghezzo L, et al. (2011) Brain volume changes in Parkinson's disease and their relationship with cognitive and behavioural abnormalities. J Neurol Sci 310:64-9.
29. Friston KJ, Ashburner J (2004) Generative and recognition models for neuroanatomy. Neuroimage 23:21-4. (Pubitemid 39119431)
30. Haxby JV, Grady CL, Horwitz B, Ungerleider LG, Mishkin M, et al. (1991) Dissociation of object and spatial visual processing pathways in human extrastriate cortex. Proc Natl Acad Sci U S A 88:1621-5. (Pubitemid 21916277)
31. Weintraub D, Dietz N, Duda JE, Wolk DA, Doshi J, et al. (2012) Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. Brain 135:170-80.
32. Apostolova L, Alves G, Hwang KS, Babakchanian S, Bronnick KS, et al. (2012) Hippocampal and ventricular changes in Parkinson's disease mild cognitive impairment. Neurobiol Aging 33:2113-24.
33. Pereira JB, Junqué C, Martí MJ, Ramirez-Ruiz B, Bargalló N, et al. (2009) Neuroanatomical substrate of visuospatial and visuoperceptual impairment in Parkinson's disease. Mov Disord 24:1193-9.
34. Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, et al. (2012) Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 72:587-98.
35. Halliday GM, McCann H (2010) The progression of pathology in Parkinson's disease. Ann N Y Acad Sci 1184:188-95.
36. Yeo BT, Krienen FM, Sepulcre J, Sabuncu MR, Lashkari D, et al. (2011) The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J Neurophysiol 106:1125-65.
37. Huang C, Mattis P, Perrine K, Brown N, Dhawan V, et al.(2008) Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 70:1470-7. (Pubitemid 351521942)
38. Schmahmann JD, Sherman JC (1998) The cerebellar cognitive affective syndrome. Brain 121:561-79. (Pubitemid 28162120)
39. Garrard P, Bradshaw D, Jäger HR, Thompson AJ, Losseff N, et al. (2002) Cognitive dysfunction after isolated brain stem insult. An underdiagnosed cause of long term morbidity. J Neurol Neurosurg Psychiatry 73:191-4.
40. Corbetta M, Shulman GL (2002) Control of goal-directed and stimulus-driven attention in the brain. Nat Rev Neurosci 3:201-15. (Pubitemid 135706590)
41. Leh SE, Petrides M, Strafella AP (2010) The neural circuitry of executive functions in healthy subjects and Parkinson's disease. Neuropsychopharmacology 35:70-85.
42. Poletti M, Emre M, Bonuccelli U (2011) Mild cognitive impairment and cognitive reserve in Parkinson's disease. Parkinsonism Relat Disord 17:579e86.
43. Jech R, Mueller K, Schroeter ML, Ruzicka E (2013). Levodopa increases functional connectivity in the cerebellum and brainstem in Parkinson's disease. Brain, in print.
44. Cerasa A, Messina D, Pugliese P, Morelli M, Lanza P, et al. (2011) Increased prefrontal volume in PD with levodopa-induced dyskinesias: a voxel-based morphometry study. Mov Disord 26:807-12.
45. Aron AR, Obeso J (2012) Is executive control used to compensate for involuntary movements in levodopa-induced dyskinesia? Mov Disord 27:339-40.
46. Biundo R, Calabrese M, Weis L, Facchini S, Ricchieri G, et al. (2013) Anatomical correlates of cognitive functions in early Parkinson's disease patients. PLoS One 8(5):e64222.
47. Jones DT, Machulda MM, Vemuri P, McDade EM, Zeng G, et al. (2011) Age-related changes in the default mode network are more advanced in Alzheimer disease. Neurology 77:1524-3.
48. Jubault T, Brambati SM, Degroot C, Kullmann B, Strafella AP, et al. (2009) Regional brain stem atrophy in idiopathic Parkinson's disease detected by anatomical MRI. PLoS One 4(12):e8247.
49. Fahn S, Elston RL, members of the UPDRS Development Committee (1987) Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB (eds). Recent developments in Parkinson's disease, vol. 2. Macmillan, New York, pp. 153-163.
50. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, et al. (2010) Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 25: 2649-53.
51. Giovagnoli AR, Del Pesce M, Mascheroni S, Simoncelli M, Laiacona M, et al. (1996) Trail Making Test: normative values from 287 normal adult controls. Neurol Sci 17: 305-309. (Pubitemid 126764956)
52. Caffarra P, Vezzadini G, Dieci F, Zonato F, Venneri A (2002) Una versione abbreviata del test di Stroop. Dati normativi nella popolazione italiana. Nuova Riv Neurol 12: 111-115. (Pubitemid 35332213)
53. Appollonio I, Leone M, Isella V, Piamarta F, Consoli T, et al. (2005) The Frontal Assessment Battery (FAB): normative values in an italian population sample. Neurol Sci 26: 108-116. (Pubitemid 40975511)
54. Spinnler H., & Tognoni G (1987) Standardizzazione e taratura italiana di test neuropsicologici. Neurol Sci 6: 1-120.
55. Caffarra P, Vezzadini G, Dieci F, Zonato F, Venneri A (2002) Rey-Osterrieth complex figure: normative values in an Italian population sample. Neurol Sci 22: 443-447. (Pubitemid 34436807)
56. Novelli G, Papagno C, Capitani E, Laiacona M, Vallar G, et al. (1986) Tre test clinici di ricerca e produzione lessicale: taratura su soggetti normali. Archo Psicol Neurol Psichiat 47: 477-506.